Neurocrine Biosciences NBIX Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on the most recent quarter.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's net debt / EBITDA?
- Neurocrine Biosciences (NBIX) reported net debt / EBITDA of 0.2× in Q1 2026.
- How has Neurocrine Biosciences's net debt / EBITDA changed year-over-year?
- Neurocrine Biosciences's net debt / EBITDA decreased by 58.5% year-over-year, from 0.6× to 0.2×.
- What is the long-term trend for Neurocrine Biosciences's net debt / EBITDA?
- Over 2 years (2023 to 2025), Neurocrine Biosciences's net debt / EBITDA has grown at a -18.6% compound annual growth rate (CAGR), from 1.2× to 0.8×.
- What does net debt / EBITDA mean?
- How many years of operating earnings it would take to pay off the company's net debt.
- How do you interpret net debt / EBITDA?
- Lower is safer; lenders often covenant around 3–4×. A negative value means net cash (more cash than debt), a position of strength. Spikes can reflect a temporary EBITDA dip rather than new borrowing.
- How does net debt / EBITDA compare across companies?
- A standard leverage yardstick across non-financial sectors; covenant thresholds vary by industry cash-flow stability.